SEC Comment Letter for REGENERON PHARMACEUTICALS, INC. (REGN) (CIK 0000872589) (REGN) — Jul 21, 2014
REGENERON PHARMACEUTICALS, INC. (REGN) (CIK 0000872589)
Date: July 21, 2014 · CIK: 0000872589 · Accession: 0000000000-14-036733
AI Filing Summary & Sentiment
File numbers found in text: 000-19034
Letter
July 21, 2014 Via E -mail Robert E. Landry Senior Vice President, Finance and Chief Financial Officer Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, New York 10591
Re: Regeneron Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 201 3 Filed February 13, 2014 File No. 000-19034
Dear M r. Landry :
We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or a ny person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1 934 and all applicable rules require.
Sincerely,
/s/ Joel Parker
Show Raw Text
July 21, 2014 Via E -mail Robert E. Landry Senior Vice President, Finance and Chief Financial Officer Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, New York 10591 Re: Regeneron Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 201 3 Filed February 13, 2014 File No. 000-19034 Dear M r. Landry : We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or a ny person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1 934 and all applicable rules require. Sincerely, /s/ Joel Parker Joel Parker Accounting Branch Chief